A multicenter, open label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy.
-
Enrollment
This study is currently enrolling. -
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
OncoVerity, Inc.
The purpose of this study is to see if the investigational study drug, called cusatuzumab, is safe and effective when given together with other standard of care drugs used to treat Acute Myeloid Leukemia (AML).
Enrollment Form
This study is currently enrolling.